A.I. VALI uses proprietary Machine Learning (ML) and Deep Learning (DL) techniques to analyze the data collected from medical images, such as endoscopy video images and tissue biopsies. Our modular A.I. tools empower our clients with accurate, reproducible and affordable platforms at a global level. These platforms have a critical impact in the early detection of cancer in order to provide the best personalized treatment model for each patient. A.I. VALI offers services in research and development, analytical validation, optimization, and validation for regulatory submissions. These services can be utilized by our clients and incorporated into the early stages of drug development through clinical trials and validation of biomarkers, or companion diagnostics (CDx), by providing precise interpretation of information on cell functioning, as well as the structure of critical proteins and biomarkers.
Total Funding: N/A
Funding Stage: Pre-Seed
Business Stage: Scaling Up
Market: B2C, B2B
Company Size: 1 to 25
Founded: 2017
